CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs